U nas zapłacisz kartą
Vita C Infusion Mikrodermabrazja - Twoje Klucze do Promiennej Skóry
Vita c infusion mikrodermabrazja
Products Ingredients Decode INCI Login Register
Login Register
Follow us on our new Insta page »
The moisturizing microdermabrasion from the Vita C Infusion line gives your skin a boost. Microdermabrasion cleanses, tones, refreshes and unifies the skin tone. Microdermabrasion dedicated to all skin types. Time [more] [more] of day to use microdermabrasion day and night. The active ingredients of the formula are camu-camu extract and sea buckthorn oil providing a powerful dose of vitamin C and exfoliating micro-crystals. [less]
The controversial history of high-dose vitamin C in cancer treatment
Utilizing high doses of vitamin C as a cancer therapy is no exception to this controversy. Nearly 60 years ago Toronto physician William McCormick observed that cancer patients often presented with severely low levels of vitamin C in their blood and featured scurvy-like symptoms, leading him to postulate that vitamin C might protect against cancer by increasing collagen synthesis. In 1972, extending this theory, Ewan Cameron, a Scottish surgeon, hypothesized that ascorbate could suppress cancer development by inhibiting hyaluronidase, which otherwise weakens the extracellular matrix and enables cancer to metastasize. He began treating terminally ill cancer patients and published a case report of 50 patients in which some of the treated patients benefited from high dose vitamin C.
So why did the Pauling and Mayo Clinic trials have different results? There are at least two crucial differences. First, the Mayo Clinic trials abruptly stopped the ascorbate administration, switching to traditional chemotherapy, when the patient developed signs of tumor progression. Thus, the overall median time of vitamin C treatment under the Mayo Clinic trials was only 2.5 months, while the Pauling and Cameron trials treated patients for the duration of the entire study period or as long as 12 years. Secondly, the Mayo Clinic trials administered 10 g of daily ascorbate to patients only orally, while the Cameron and Pauling trials administered their vitamin C both orally and intravenously. This difference in the two dosage routes proved highly consequential.
What Drugs Interact with High-Dose Vitamin C?
A drug interaction is a change in the way a drug acts in the body when taken with certain other drugs. High-dose vitamin C, when combined with some anticancer drugs, may cause them to be less effective. So far, these effects have been seen only in some laboratory and animal studies. No clinical trials have been done to further research these drug interactions in humans.
Laboratory studies and animal studies have been done to find out if high-dose vitamin C may be useful in preventing or treating cancer.
Laboratory studies
Many laboratory studies have been done to find out how high-dose vitamin C may cause the death of cancer cells. The anticancer effect of vitamin C in different types of cancer cells involves a chemical reaction that makes hydrogen peroxide, which may kill cancer cells.
Laboratory studies have shown the following:
- Treatment with high-dose vitamin C slowed the growth and spread of prostate, pancreatic, liver, colon, malignant mesothelioma, neuroblastoma, and other types of cancer cells.
- Combining high-dose vitamin C with certain types of chemotherapy may be more effective than chemotherapy alone:
- Ascorbic acid with arsenic trioxide may be more effective in ovarian cancer cells.
- Ascorbic acid with gemcitabine may be more effective in pancreatic cancer cells.
- Ascorbic acid with gemcitabine and epigallocatechin-3-gallate (EGCG) may be more effective in malignant mesothelioma cells.
However, not all laboratory studies combining vitamin C with anticancer therapies have shown benefit. Combining dehydroascorbic acid, a particular form of vitamin C, with chemotherapy made it less effective in killing some kinds of cancer cells.
Animal studies
Studies of high-dose vitamin C have been done in animal models (animals given a disease either the same as or like a disease in humans).
Intravenous High-Dose Vitamin C in Cancer Therapy
Lewis Cantley received his Ph.D. from Cornell University and did his post-doctoral work at Harvard University. He was formerly a professor in the Departments of Systems Biology and Medicine at Harvard Medical School in Boston. He is current the Meyer Director and Professor of Cancer Biology at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine in New York City. Jihye Yun received her Ph.D. from Johns Hopkins University, School of Medicine under the mentorship of Bert Vogelstein and did her post-doctoral work with Lewis Cantley at Weill Cornell Medicine. She is currently an Assistant Professor and a CPRIT scholar at Baylor College of Medicine in Houston.
The discovery and isolation of vitamin C was one of the most important advances in improving human nutrition. Scurvy, a severe vitamin C deficiency disease characterized by weakness, lethargy, easy bruising and bleeding, was particularly problematic for sailors on long voyages during the 16th century, where access to fresh fruits and vegetables was limited. In fact, scurvy was the leading cause of naval deaths between the 16th and 18th centuries, killing more sailors than all battles, storms and other diseases combined. It wasn’t until 1747 that Scottish naval physician James Lind demonstrated that consuming oranges and lemons cured and prevented scurvy. However, it took scientists nearly two more centuries to identify the nature of the curative substance contained in citrus fruits, now commonly known as vitamin C. The search for this elusive substance ended in 1932 when Albert Szent-Gyorgyi, a Hungarian biochemist, isolated and identified a 6-carbon carbohydrate, hexuronic acid, as the anti-scurvy factor. Shortly thereafter, Szent-Gyorgyi renamed it “a-scorbic acid”, a reference to its anti-scorbutic properties, and later went on to receive the Nobel Prize in Physiology and Medicine in 1937 for his discoveries.
